UltraSight aims to revolutionize cardiac sonography through the power of machine learning to enable more accurate and timely clinical decisions. UltraSight's AI-driven software provides real-time guidance and quality assessment to allow healthcare professionals, regardless of sonography proficiency, to consistently perform high-quality cardiac ultrasound in a variety of settings at the point of care, including clinics, community hospitals, ambulances, and remote and rural areas. UltraSight's AI real-time guidance software has FDA 510(k) Clearance, is UKCA and CE Marked, and has Israeli AMAR Clearance to assist medical professionals in performing cardiac ultrasound scans. UltraSight's software is an accessory to compatible general-purpose, diagnostic ultrasound systems. Full labeling is available at https://ultrasight.com/regulatory-approvals-and-labeling/. In 2022, UltraSight won the Bristol Myers Squibb Improving Cardiovascular Disease Outcomes Challenge as the most "innovative cardiac technology." Additionally, the company was awarded a patent for its real-time guidance solution for ultrasound devices.